Journal of cancer policy
Progression-free survival is strongly associated with overall survival in relapsed/refractory diffuse large B-cell lymphoma in the CAR T-cell era.
Alexander M Gorzewski, Rebecca Z Steuer, Charmi Trivedi, Kaavya Mandi, Christina A Raker, Charles J Milrod, Ari R Pelcovits
Published: 202510.1016/j.jcpo.2025.100699
Abstract
INTRODUCTION: In clinical trials for diffuse large B-cell lymphoma (DLBCL), progression-free survival (PFS) has been used as a validated surrogate endpoint to help expedite drug development and regulatory approval. The advent of chimeric antigen rece…
Preview only. Read the full abstract at the source